Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 06.21
    2018

    Addex Shareholders Approve All Resolutions at Annual General Meeting

  • 04.30
    2018

    Addex Reports 2017 Full Year Results and Provides Corporate Update

  • 03.29
    2018

    Addex Sucessfully Raises CHF40 million in Capital Increase

  • 03.20
    2018

    Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association

  • 03.19
    2018

    Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting

  • 03.05
    2018

    Addex Secures Investor Commitment for CHF40 million Capital Increase Following Successful Completion of Book Building Process

  • 02.23
    2018

    Addex Publishes Extraordinary General Meeting Invitation

  • 02.15
    2018

    Addex Launches CHF40 million Capital Increase with Commitments from Specialist US Healthcare Investors

  • 02.07
    2018

    Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management

  • 02.05
    2018

    Addex Provides Key Financial Indicators and Trading Update

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics